Clinical Trial: A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07200908) titled 'A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)' on Sept. 16.

Brief Summary: This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.

Study Start Date: Aug. 27

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis D Infection

Intervention: DRUG: Brelovitug 300 mg

Route of admin...